Flucocinolone Acetonide (steroid) was approved by the FDA in 2005 for uveitis. PSDV used the Retisert delivery system to deliver the steroid. Since then, PSDV has been developing even smaller devices to deliver drugs. The latest will be administered with a small needle by the eye doctor. Revenues from Alimera to PSDV could be half of the PSDV current market cap. Flucocinolone is already approved. The delivery systems of PSDV are already approved. The current and newest one is even better than Retisert and Vitrisert. This company stock will move in a big way to the upside. There will be other indications for chronic eye problems that this delivery system can and will address going forward.
You mention Rosey, I like him. Market just taking a humping, you scared little thing. Quit being a whimpy mouse, or Siam Kitty will have to get you in shape and give you something real scary to worry about.